Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial

CAR-T Digest - August 2020

04 Feb 2025: Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial

Pyxis Oncology announced progress in its clinical program for PYX-201, an ADC targeting extradomain-b fibronectin (EDB+FN), a structural component in the tumor ECM
Two trials are recruiting, PYX-201 as monotherapy in R/M HNSCC and in combination with Merck’s KEYTRUDA for R/M HNSCC and other solid tumors
The Phase 1/2 combination trial (PYX-201-102) is set to begin dosing in Q1 2025, exploring PYX-201 with pembrolizumab in multiple indications, including breast cancer and TNBC
PYX-201 delivers the AUR-0101 payload to the tumor microenvironment, potentially enhancing pembrolizumab’s efficacy by promoting T-cell infiltration
Pyxis Oncology aims to develop innovative therapies for cancers with limited treatment options, positioning PYX-201 as a potential breakthrough therapy